All News

CART

CAR-T Product Shows Early Promise in Lupus

Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months.

Read Article
IPF.CT_.jpg

High-Resolution CT in CTD-Interstitial Lung Disease

Jack Cush, MD

A systematic review and meta-analysis examined the role of high-resolution computed tomography (HRCT) in diagnosing and characterizing interstitial lung disease (ILD) associated with connective tissue diseases (CTDs).

Read Article
GCA temporal artery

Methylprednisolone plus Methotrexate in Giant Cell Arteritis

Jack Cush, MD

What is the optimal glucocorticoids (GC) regimen in giant cell arteritis (GCA)? Does methotrexate (MTX) work in GCA?  

Read Article
RheumNow Podcast square

Big Fat FDA Pink Slip (9.19.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. 

Read Article
Covid lung pneumonia corona (keep)

Did Hydroxychloroquine Reduce COVID-19 Mortality?

Jack Cush, MD

A multicenter study investigated the association between hydroxychloroquine (HCQ) dosage and COVID-19 mortality among hospitalized patients from multiple medical centers in China. The analysis focused on dose effects of HCQ on mortality.

Read Article
GLP-1.pink

GLP-1 Drugs Reduce Rheumatoid Arthritis Symptoms

MedPage Today

Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved cardiovascular biomarkers, a small retrospective study indicated.

Read Article
Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 RCTs, 1175 SLE pts show higher CCI scores predicts increased all-cause mortality (OR 3.92(95% CI: 2.74–5.60) https://t.co/LXfsGo9iJq https://t.co/eK31lnFrJk

Links:

Dr. John Cush RheumNow ( View Tweet)
Single-center retrospective study 49 pts w/ primary angiitis CNS (PACNS) stratified by vessel size. Vessel size dx by imaging & neuroradiologists. Small vessel involv(n  9) was significantly assoc w/ +Biopsies, CTX use, functional decline & more relapses. https://t.co/DF6DknoPxY https://t.co/puc6nvEAut

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review of 139 RCTs(9644 pts) & 12 Rx options for knee OA (KOA) shows simple Rx is best. For pain and function, knee brace was best, followed by exercise, and US worst. For total WOMAC best was hydrotherapy, then exercise & LaserTx. (Short wave diathermy worst) https://t.co/sN9TxJGn6N
Dr. John Cush RheumNow ( View Tweet)
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/Kxbarq9tiD
Dr. John Cush RheumNow ( View Tweet)
Study of urinary soluble CD163 levels in 214 SLE pts (129 w/ LN), found urinary CD163 highly correlates w/ UPCR, active vs inactive states, predicts Renal Bx histologic activity (AUC 0.962) & renal dz flares & allows prediction of complete, partial and non-responders https://t.co/HNKAuFDgPG
Dr. John Cush RheumNow ( View Tweet)
SARD-ILD: Significant diagnostic and treatment delays Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? https://t.co/WyccifEHtY https://t.co/S6X5AhZCjz

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club! We’ll dive into two pivotal ILD studies: 📄 FIBRONEER (Nerandomilast in PPF) – NEJM 2025 📄 RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet Panelists: Dr. Toby Maher, Dr. Shervin Assassi Moderator: https://t.co/l8EkX2hkLs
Dr. John Cush RheumNow ( View Tweet)
ILD and Mortality in Systemic Autoimmune Rheumatic Diseases Dr. Bryant England, Lincoln, NE, discusses interstitial lung disease and mortality in systemic autoimmune rheumatic diseases (SARDs), as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month https://t.co/wtg9Te6oth
Dr. John Cush RheumNow ( View Tweet)
Patient Resource: The Hidden Connection - ILD and Rheumatic Disease Dr. Iazsmin Bauer Ventura, Chicago, talks about ILD as a window to systemic disease as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/8rJm4O3hHU
Dr. John Cush RheumNow ( View Tweet)
RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortality. retrospective cohort study using the Mass General Brigham Biobank 221 RA-LD cases (151 RA-ILD, 70 RA-BR). RA-LD higher mortality (34 vs 13/1000PY; HR

Dr. John Cush RheumNow ( View Tweet)

STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months. https://t.co/HLLhwgcVrS https://t.co/MKpeXhVdoe

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+ 14%, 88% Rx w/ IS or antifibrotics. 24% died, 7.5% transplant. Comorbidies were common; mean CCI 3.2; IPAF mortality worsened by

Dr. John Cush RheumNow ( View Tweet)

Commercial claims analysis of 8855 adults w/ axSpA and/or PsA, 1771 who had joint replacements. JAK inhibitor use did not significantly reduce joint replacement (OR 0.67; 0.41–1.08), BUT TNFi, Non-TNFi biologics & DMARD users had signif fewer surgeries (OR ~0.65) vs NSAID users https://t.co/vnBnFcPxGw
Dr. John Cush RheumNow ( View Tweet)
SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurements. SUA levels had NO ASSOC. w/ all-cause mortality, disability-free survival, CV Dz, MACE, cancer mortality, cognitive decline, or dementia. In females, low SUA https://t.co/VY6NJsetW9
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×